Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!
Expand chart

Data: The Malaria Atlas Project; Map: Harry Stevens/Axios

The fight against malaria in the past couple decades has largely had a positive trajectory — since 2000, there have been 7 million lives saved and about 1 billion cases prevented — but recently there's been pockets of plateauing or increased infections in the world.

Why it matters: Malaria parasites are starting to show more resistance against insecticides and drug treatments. Combined with political instability and lack of necessary funding, the goal of eliminating malaria now requires urgent action with new tools no longer using the "one size fits all" method, a group of malaria experts tell Axios.

"We need to get the right combination of interventions to the right people at the right place to save lives."
— Jennifer Gardy of the Gates Foundation

Background: The female Anopheles mosquito is the vector of malaria parasites (there are now more than 100 species). When diagnosed early, malaria is considered treatable for most patients, depending on the particular parasite.

  • Plasmodium falciparum, found mostly in Africa, is the most deadly parasite as it can cause cerebral malaria. Plasmodium vivax tends to be less deadly but is more prominent throughout the world, including in South America.

What's new: "For the first time [in recent history] we're seeing cases rise in high burden areas," says Michal Fishman of the nonprofit Malaria No More.

  • The reasons for the uptick are mainly due to 3 issues: higher population movement from refugees, a lack of necessary funding, and the parasites are becoming more resistance to insecticides and drug treatments, according to Simon Hay of the University of Washington's Institute for Health Metrics and Evaluation (IHME) who tracks malaria via maps.
  • Malaria was eliminated in the U.S. in 1951, but the country still has the Anopheles mosquitos that can bite an infected person and transmit to others.

The group of experts from nonprofit and for-profit groups tell Axios the following steps are needed...

1. Decisive actions from governments are key, mainly through policy and funding.

  • "Political will is such a critical factor in driving results in Africa," says Abbott's Damian Halloran. Fishman agrees, and points to Zambia's president as one who tracks their malaria effort every day.
  • The World Health Organization, which has called for 10 countries to be malaria-free by 2020, pointed out last week that China is a good example after eliminating malaria "became the joint goal of 13 ministries, including health, finance, industry, and education. The results were impressive and the country has gone from 30 million cases in the 1940s to zero indigenous cases in 2017."
  • Yes, but: Hay warns there's a $2 billion funding shortfall in WHO's malaria plan.

2. New tracking technologies can assist.

  • Real-time mapping is a tool researchers and advocates can use to pinpoint where to focus resources and expertise.
  • The Malaria Atlas Project at the University of Oxford and IHME published 2 studies in The Lancet on Wednesday mapping P. falciparum and P. vivax. "We've seen spectacular successes in many places, but a plateauing in some places and a resurgence in others," Hay says. Venezuela and Yemen are 2 places in particular that have seen more malaria due to political instability, Hay adds.
  • IR Mapper tracks reports of insecticide resistance in mosquitos.

3. New diagnostics and preventative measures.

  • Bed nets need to be improved to combat growing drug resistance, according to Patrick Sieyes, regional director for Vestergaard, a company that produces nets. While long-lasting treated nets are considered to be a key reason malaria cases have dropped, "we're seeing a plateau and even a reversal [in some cases] ... we're very concerned," Sieyes says. In response, the company recently developed a new version of the Permanet plus the IR Mapper app noted above.
  • Fast, reliable testing is needed to help people immediately determine if the person has malaria or not, Halloran says. Abbott has created rapid diagnostic tests for malaria that can detect it even in people who show no visible symptoms of the disease, he says. This is important because many other illnesses show similar symptoms, he adds.
  • CRISPR technology can be used to help quickly detect viral biomarkers of malaria via a saliva or urine sample, says Trevor Martin, co-founder and CEO of Mammoth Biosciences, which is developing such a test.
  • Gardy says that genomic epidemiology is the way to move forward because "by reading the DNA sequence of either the parasite or the mosquito vector," a plan of action can be created for that region.

An effective vaccine would be another important tool in the arsenal, Gardy says. A pilot program has started in Malawi and Ghana testing a new malaria vaccine called RTS,S against the deadly P. falciparum, but it faces some issues like efficacy and accessibility (it requires 4 shots). It will be brought into Kenya in July.

Go deeper:

Go deeper

27 mins ago - World

Iran's nuclear dilemma: Ramp up now or wait for Biden

Illustration: Annelise Capossela/Axios

The world is waiting to see whether Iran will strike back at Israel or the U.S. over the assassination of Mohsen Fakhrizadeh, the architect of Iran's military nuclear program.

Why it matters: Senior Iranian officials have stressed that Iran will take revenge against the perpetrators, but also respond by continuing Fakhrizadeh’s legacy — the nuclear program. The key question is whether Iran will accelerate that work now, or wait to see what President-elect Biden puts on the table.

Updated 1 hour ago - Health

U.K. first nation to clear Pfizer coronavirus vaccine for mass rollout

A health care worker during the phase 3 COVID-19 vaccine trial by Pfizer and BioNTech in Ankara, Turkey, in October. Photo: Dogukan Keskinkilic/Anadolu Agency via Getty Images

The United Kingdom's government announced Wednesday it's approved Pfizer-BioNTech's COVID-19 vaccine, which "will be made available across the U.K. from next week."

Why it matters: The U.K. has beaten the U.S. to become the first Western country to give emergency approval for a vaccine that's found to be 95% effective with no serious side effects against a virus that's killed nearly 1.5 million people globally.

3 hours ago - World

Biden says he won't immediately remove U.S. tariffs on China

President-elect Joe Biden during an event in Wilmington, Delaware, on Tuesday. Photo: Alex Wong/Getty Images

President Trump's 25% tariffs imposed on China under the phase one trade deal will remain in place at the start of the new administration, President-elect Biden said in an interview with the New York Times published early Wednesday.

Details: "I'm not going to make any immediate moves, and the same applies to the tariffs," Biden said. He plans to conduct a full review of the current U.S. policy on China and speak with key allies in Asia and Europe to "develop a coherent strategy," he said.